- Accuracy (of measurement)
- Closeness of the agreement between the result of a measurement and a true value of the property being measured.
Note 1: Accuracy is a qualitative concept.
Note 2: The term “precision” should not be used for accuracy
- Active (screen active)
- A sample that produces a response or signal above a defined threshold at a tested concentration in a single assay or screen. Note: When the properties and identity of an active or hit are confirmed by subsequent experiment it becomes a confirmed active. See also inactive.
- Activity (e.g. in a primary screen)
- Response to a test sample measured in an assay or screen.
Note: Typically expressed as a percentage with regard to assay controls
- Activity Distribution
- Graphical representation of the number of samples present in each activity range.
Note: Often shown as a frequency distribution graph, it provides an overview of the screening results and typically allows the determination of the overall background signal and threshold for selection of actives.
- Active Threshold
- Minimum activity that defines actives in a primary screen. It is usually expressed as percentage of inhibition or stimulation. This would typically be calculated as test sample values >3x robust standard deviation of control samples.
- Observation, effect, or result that is inaccurate because it is produced by the methodology used in scientific investigation or by experimental error. See also false positive, false negative.
- Test run to determine pharmacologic response, often in the presence of a test substance. Assays are typically miniaturized and run in high throughput to identify inhibitors or activators as a first step in drug discovery. Assays may be run with isolated cellular components or using whole cells, with a variety of readouts. See also assay development, assay miniaturization.
- Assay Development
- Design and optimization process by which an assay is made ready for routine screening. Success criteria include expected responses to known standards, reproducibility, robustness and cost. The specifics of the criteria are set by institutions for screening and by the FDA for clinical use.
- Assay Miniaturization
- Experimental design aimed at decreasing the reaction volume of an assay and consequently the amount and cost of reagents. Examples: Adaptation of assays from test tube or 96 well format to high-density microplates (e.g. 1536 wells).
- Assay Transfer
- The process by which an assay is transferred from one organization to another (e.g. from an academic investigator to GSK).
- Assay Validation
- Experiments conducted to verify that the output measurement of the assay is consistently reflective of the activity against the target. Results are compared internally over multiple runs and externally (when available) to existing literature parameters such as Kd, Ki, Km, or EC50.
- Mechanization with process control, where process means a sequence of manipulations.
- Magnitude of a signal produced in an assay or screen in the absence of a test substance. Also, signal detected from an assay in the absence of target activity; often equivalent to negative control.
- Candidate Selection
- Preclinical studies (medicinal chemistry, pharmacology, drug metabolism and pharmacokinetics) are performed on leads to identify a lead candidate compound. Several activities, such as pharmacology, in vivo efficacy, drug metabolism and pharmacokinetics, and experimental toxicology are performed on the lead candidate compound. This data package forms the basis of a candidate selection, after which the drug candidate is further subject to additional preclinical development activities. These preclinical activities provide the basis for an Investigational New Drug (IND) application to the FDA for permission to initiate clinical testing in humans.
- Chemical Probe (tool compound)
- A compound (or chemical series) that has sufficient potency, selectivity, cell permeability and bioavailability to be used for the validation of a biological hypothesis when used in cellular or animal models of disease.
- Informatics technologies that integrate chemical data with analytic and molecular design tools. Cheminformatics applications provide access to compound-related information, including chemical structure, properties, structure-activity relationships.
- Chemistry Scale-up
- The process of making gram scale amounts of drug substance, for example to allow for toxicology studies.
- Compound Collection (compound library, e.g. HTS collection)
- Set of chemicals that has been assembled and annotated for easy storage and retrieval and that is available for screening. Generally consists of compounds synthesized by combinatorial or standard synthetic methods, purchased from commercial sources or of samples of natural products either as pure samples or as mixtures.
- Compound Profiling
- Testing a set of (often structurally related) molecules against a series of assays with the aim of providing insight into the pharmacological structure-activity relationships of chemical series.
- A standard of comparison by which experimental results are evaluated. A control differs from the experiment in a single variable, and enables the assessment of significance of experimental results.
- Confirmed Active
- A sample that produces a response above a defined activity threshold in repeat experiments. See also active and confirmation screen.
- Confirmation Screen
- A screen in which putative actives identified from a primary screen are re-tested (typically in duplicate) to confirm their initial activity.
- Screen in which test samples are assessed against a target for unwanted activity. This target may or may not be structurally or functionally related to the intended target.
- Dose Response (concentration response)
- Figure quantifying the effect of a compound in an assay at varying concentrations. Note: This experiment provides information about the potency and efficacy of the tested compound. Classical thermodynamics of a 1:1 interaction between compound and target generally results in a hyperbolic increase of the assay signal upon linear increase in compound concentration. Thus, compound concentration responses are usually determined using logarithmic serial dilutions, e.g. 10 µmol/L, 1 µmol/L, 100 nmol/L, 10nmol/L, 1 nmol/L. Related terms: Ki, Kd, EC50, IC50.
- Dose Response Screen
- A screen in which confirmed actives are re-test against the same assay format, but where dose response curves (typically consisting of 11 doses of a 3-fold dilution series starting at 50 uM in duplicate) are generated.
- Drug Metabolism
- The process of modification and breakdown of drugs within a living organism.
- Encoded Library Technology (ELT)
- Combines the power of affinity based enrichment with combinatorial chemistry to enable the rapid selection of hits from small molecule libraries containing up to several billion compounds. Each ELT library molecule carries a unique DNA tag which encodes the chemical composition of the small molecule. Libraries are "selected" against protein targets by affinity based methods. Enriched binders are isolated, sequenced, and translated back into their corresponding chemical structures. The hit compounds are then synthesized without the DNA tag and assayed for activity against the target.
- Effective Concentration (EC)
- Concentration of a substance that causes a defined magnitude of response in a given system. EC50 is the median concentration that causes 50% of the maximal response. This usually refers to an agonist in a receptor system. The value of this quantity may result from either an increase or a decrease in a biological function.
- False Negative
- Assay result in which a sample known to be active does not produce either the expected signal or a signal above the activity threshold.
Note: A false negative can occur when an assay lacks appropriate discriminatory power, when the threshold is inappropriately set, or as a result of mistaken identity of the test sample. A false negative can also occur due to specific compound properties such as poor solubility, high non-specific protein binding, or interference with the assay signal.
- False Positive
- Assay result in which a sample known to be inactive produces a signal or response above the activity threshold.
Note: A false positive can occur when an assay lacks appropriate discriminatory power, when the threshold is inappropriately set, as a result of certain physical properties of the substance
(e.g., a fluorescent compound in a fluorescence intensity assay, aggregation), or as a result of mistaken identity of the substance.
- Functional Assay
- Assay in which the biological or physiological activity of the target is measured. Example: An assay in which an agonist stimulates, in receptor-transfected cells, the production of a second messenger that is detected with a fluorescence readout.
- Heterogeneous Assay
- Assay in which the response is detected only after the physical separation by methods such as filtration or centrifugation of one or more assay components. See also heterogeneous binding assay and homogeneous assay.
- High-Content Screening Assay
- Assay that produces multiple biological readouts.
Note: Most commonly used in relation to the mathematical (quantitative) analysis of an image acquired using an automated microscope. Analysis algorithms are used to quantify cellular parameters (e.g. number, motility, neurite outgrowth, size, shape) and subcellular events (e.g. receptor internalization, protein translocation, protein expression nuclei shape).
- High-Throughput Screening (HTS)
- A method in which a large number of compounds (in the case of GSK, ~2 million) are tested against optimized assays in a relatively short period of time. Typically, these assays are carried out in microplates in 1536-well format, using automated or robotic technologies.
- Sample that produces confirmed activity above the hit threshold in an assay and whose structural identity has been confirmed. A substance becomes a hit when the properties of an active are confirmed by elimination of false positive results and artifacts.
Note: In the past, the terms confirmed hit, true hit and confirmed active were used with this meaning.
- Hit Expansion
- The process of exploring structurally related compounds around chemical clusters of initial interest from a screen, typically following hit qualification.
- Hit Rate
- The portion of hits from a screen that displays confirmed activity beyond a minimum defined level, the hit threshold. It is expressed as a percentage of the number of samples screened.
- Hit Qualification
- An experimental process by which samples which are shown to be active from a screen are demonstrated to be confirmed hits via demonstration that their pharmacological activity is due to a productive mechanism driven by a confirmed chemical structure.
- Homogeneous Assay
- Assay in which all reagents and reactants are of a uniform phase (typically, liquid phase) and assay response is detected without the need for physical separation of assay components. See also heterogeneous assay.
- IC50 (Inhibition Concentration 50)
- The concentration of an enzyme inhibitor or receptor antagonist that reduces the enzyme activity or agonist response by 50%.
Note: IC50 values are influenced by experimental conditions (substrate or agonist concentration—which should be specified). Related terms: EC50, inhibition constant, Ki.
- Sample that, at the tested concentration, does not produce a response above the hit threshold in an assay.
Note: A sample may also be designated as inactive when attempts to confirm an active fail.
See also artifact, false positive, hit.
- Lead Compound
- The best exemplar of a chemical series that has a pharmacological or biological activity and has suitable chemical properties to act as a starting point for further chemical optimization. Typically, a lead shows appropriate activity at the target, demonstrates activity in a relevant cell-based assay and has a tractable structure-activity relationship (SAR) with potential to achieve the required activity, selectivity, physicochemical characteristics, patentability and bioavailability of a candidate quality molecule.
- Lead Identification
- Process that is targeted toward the generation of at least one compound series patentable that meets the requirements for progression to lead optimization. It typically encompasses the steps from the detection of initial activity (via high throughput screening and other lead finding activities) through hit confirmation and hit-to-lead activities.
- Lead Optimization
- Process in which the drug-like properties of an initial lead or lead series are improved. Typically, biological activity will be enhanced, in vivo efficacy will be demonstrated and compounds with a physicochemical, pharmacological and toxicological profile consistent with progression to the clinic will be identified.
- Lead Series
- A series of structurally related compounds that have pharmacological or biological activity and has suitable chemical properties to act as a starting point for further chemical optimization. Typically, a lead series shows appropriate activity at the target, demonstrates activity in a relevant cell-based assay and has a tractable structure-activity relationship (SAR) with potential to achieve the required activity, selectivity, physicochemical characteristics and bioavailability of a candidate quality molecule.
- Medicinal Chemistry
- Medicinal chemistry is the chemistry discipline concerned with the design, development and synthesis of pharmaceutical drugs. The discipline combines expertise from chemistry and pharmacology to identify, develop and synthesize chemical agents that have a therapeutic use and to evaluate the properties of existing drugs.
- Random fluctuations occurring in a signal that are inherent in the combination of instrument and method.
- Pharmacodynamics (PD)/Pharmacodynamic assay (PD assay)
- The branch of pharmacology and its suite of assays concerned with the effects of drugs on the human body and the mechanism of their action.
- Pharmacokinetics (PK)/Pharmacokinetic assay (PK assay)
- The study/assays focused on determining the time course of drug absorption, distribution, metabolism and excretion (ADME) of a drug substance.
- Primary Screen
- Initial screen applied to assess the activity of a collection of compounds and identify hits or actives against a biological target of interest. This screen identifies actives from a library. See also secondary screen.
- Primary Screening Assay
- This is the assay format that will need to support HIT identification, typically up to 3 million wells for a full HTS.
- Phenotypic Assay
- An assay that monitors observable physical or biochemical changes within a cell that are not dependent upon a specific target. Such assays are typically designed to be as disease-relevant as possible, for example using primary or stem-cell derived materials.
- Physico-chemical Properties
- Molecular properties concerned with, or relating to physical chemistry of molecules. Physico-chemical influences a wide range of molecular properties such as pKa, solubility, and lipophilicity.
- Dose of drug required to produce a specific effect of given intensity as compared to a standard reference. Potency is a comparative rather than an absolute expression of drug activity. Drug potency depends on both affinity and efficacy. Thus, two agonists can be equipotent, but have different intrinsic efficacies with compensating differences in affinity. More potent compounds have lower IC50 or EC50 values implying that less is needed for an effect.
- Closeness of agreement between independent test results obtained by applying the experimental procedure under stipulated conditions. The smaller the random part of the experimental errors that affect the results, the more precise the procedure. A measure of precision (or imprecision) is the standard deviation.
- The proteins, small molecule substrates, cells, viruses, lysates, membranes that are needed to run assays.
- Reagent Generation
- Process by which all of the biological materials (e.g. target proteins, substrate, ligands, cell lines) required to run an assay/screen are developed and/or procured. See also assay development.
- Reagent Scale-up
- Process by which all of the biological materials (e.g. target proteins, substrate, ligands, cell lines) required to run a large-scale screen are developed and/or procured. For example, an HTS campaign requires sufficient material to run around 3 million assay wells.
- Closeness of agreement between independent results obtained with the same method on identical test material but in distinct experiments (different operators, different apparatus, different laboratories, and/or after different intervals of time). The measure of reproducibility is the standard deviation qualified with the term “reproducibility” as reproducibility standard deviation. In some contexts, reproducibility may be defined as the value below which the absolute difference between two single test results on identical material obtained under the above conditions may be expected to lie with a specified probability.
- Extent to which an assay or screen exhibits high discriminatory power and produces a low number of false negative and false positive results.
- Automated device that performs tasks (i.e., screen functions) that would normally be performed by a human.
Note: A robot in laboratory automation is usually used to move microplates in an automated assay procedure and usually consists of either a robotic arm with at least three degrees of freedom or a plate gripper.
- Quality Control
- Operation or series of operations that contributes to the validation of screening results by establishing the acceptable limits of performance of internal controls. Examples: Validation of liquid handling devices and plate readers, determination of the Z' factor and use of assay controls, and post-experiment controls.
Note: Results of a screen are validated only after a set of quality controls has been performed.
- Screen (Screening Campaign)
- The execution, analysis, and interpretation of a large number of assays to evaluate the activity of a collection of samples against a target, pathway or in a phenotypic screen.
- Screen Validation
- Assay conditions, as determined by assay validation, are performed in the chosen plate format with an acceptable signal to background ratio as described by the Z' factor. Validation typically requires testing a number of samples a minimum of three times and allows for the estimation of false positives, false negatives and the selection of statistically significant thresholds.
- Secondary Screen
- Screen applied to independently confirm actives from the primary screen.
Note: A secondary screen may employ an assay that differs in type from the primary screen (biochemical assay vs. cell based assay), or it may be of the same type with different readout.
- Selectivity Assay
- Assay used to determine the relative potency of active or lead compounds towards an alternative target. A selectivity assay (or panel of assays) may include targets of the same family or unrelated targets.
- Specificity Assay
- This is an assay that can be used to triage the screen hits and eliminate false positives and/or false negatives.
- Structure-Activity Relationship (SAR)
- Association between specific aspects of molecular structure and defined biological action.
- Biological molecule, such as an enzyme, receptor, pathway of phenotypic response, whose activity and function is the focus of a screen and/or drug discovery effort.
- Tool Compound (chemical probe)
- A compound (or chemical series) that has sufficient potency, selectivity, cell permeability, and bioavailability to be used for the validation of a biological hypothesis when used in cellular or animal models of disease.
- Number of results that can be generated in a given timeframe. In high-throughput screening (HTS), throughput is often defined by the number of assay samples that can be processed in a day (e.g. 50,000 samples per day). Related terms: high throughput, ultra-high throughput.
- Z' factor
- Dimensionless statistical parameter that is used extensively in biomolecular screening. The Z' factor is a characteristic of an assay without the intervention of test compounds. It provides a practical index of the quality and reliability of the assay, and can be used as a guide to assay development and optimization where the standard deviations of the high and low controls and μc+ and μc- are the means of the high and low controls, respectively. The useful range of Z' values is from 0 (very poor) to +1 (excellent). In most cases, a Z' factor greater than 0.6 is required for an assay to be accepted for HTS.
All definitions are from internal GSK processes or adapted from:
- Steinmetz et al. 2009, http://www.biomedcentral.com/1471-2377/9/S1/S2)
- Pure Appl. Chem., ASAP Article doi:10.1351/PAC-REC-09-05-03 © 2011 IUPAC, Publication date (Web): 7 February 2011
- Society for Laboratory Automation and Screening